Company news

Ultragenyx Pharmaceutical Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

June 2, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

May 13, 2025

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

May 6, 2025

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

May 5, 2025

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

April 29, 2025

Ultragenyx to Participate at Investor Conferences in March

February 23, 2025

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

February 17, 2025

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

February 12, 2025

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

February 5, 2025

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Redu...

February 4, 2025

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

January 11, 2025

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

December 19, 2024

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

December 18, 2024

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

December 18, 2024

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

November 8, 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

November 4, 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

October 28, 2024

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

October 6, 2024

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

October 2, 2024

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

September 25, 2024

Ultragenyx to Participate in Investor Conferences in September

August 28, 2024

Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update

July 31, 2024

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

July 24, 2024

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

July 23, 2024

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

July 16, 2024

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2024

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 11, 2024

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

June 11, 2024

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

June 10, 2024

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

May 29, 2024

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

May 6, 2024

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

May 1, 2024

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

April 29, 2024

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

April 29, 2024

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

April 24, 2024

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

April 14, 2024

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

April 11, 2024

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

April 11, 2024

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

February 14, 2024

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

February 7, 2024

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

February 5, 2024

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

February 4, 2024

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

January 24, 2024

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

January 6, 2024

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

January 3, 2024

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

January 2, 2024

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

December 17, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.